Guideline for the management of adults with ANCA-associated vasculitis
We have produced evidence-based recommendations for treatment giving a grade of recommendation (from A to C) and an algorithm to illustrate the approach to the management of a patient with newly diagnosed AAV.
Eligibility criteria
Eligibility for treatment and use of this guideline depends on the assumption that a definite diagnosis of vasculitis has been made. The following criteria must be fulfilled prior to a diagnosis of vasculitis:
A. Symptoms and signs characteristic of systemic vasculitis. B. At least one of the following:
1. Histological evidence of vasculitis and/or granuloma formation, 2. Positive serology for ANCA (either cANCA/PR3 or pANCA/MPO), 3. Specific indirect evidence of vasculitis.
C. No other diagnosis to account for symptoms or signs.
Exclusion criteria
It is important to consider other causes of systemic illness, especially malignancy, infection (particularly bacterial endocarditis) and drugs.
Treatment
Treatment for vasculitis requires induction of remission followed by maintenance (A). Current treatment is based on assessing the severity and extent of disease and subdividing the disease into three groups: (i) localized and/or early, (ii) generalized disease with threatened organ involvement and (iii) severe/life threatening disease (C).
Localized/early systemic disease
Treatment should be with either cyclophosphamide or methotrexate. Methotrexate may be associated with a higher relapse rate (A). Evidence of progression or relapse should be treated with cyclophosphamide (B). Localized disease can cause significant local destruction and requires treatment with cyclophosphamide treatment (C).
Generalized/threatened organ involvement
Initial treatment of generalized/organ threatening disease should include cyclophosphamide and steroids (A). Cyclophosphamide may be given as continuous low dose oral treatment or by intravenous pulses initially at 2-week intervals and then 3 weekly (A). There is no difference in remission rates and no increased risk of relapse between IV and oral regimens (A). Continuous low dose oral cyclophosphamide was associated with a higher total cyclophosphamide dosage and a significant increase in infection risk. Transfer to maintenance therapy at 3 months when receiving continuous low dose oral cyclophosphamide and at 3-6 months when receiving pulsed intravenous cyclophosphamide if successful disease remission has been achieved (A). In both cases, the aim should be for a maximum duration of therapy of 6 months where successful disease remission has been achieved.
Severe/life threatening disease
Patients with AAV presenting with severe renal failure (creatinine >500 mol/l) should be treated with cyclophosphamide (either pulsed IV or continuous low dose oral) and steroids, with adjuvant plasma exchange (A). Plasma exchange should also be considered in those with other life threatening manifestations of disease such as pulmonary haemorrhage (C).
Steroids
Steroids are usually given as daily oral prednisolone. Initially at relatively high doses; 1 mg/kg up to 60 mg (A). Intravenous steroids (250-500 mg methylpredinisolone) are sometimes given just prior to/with the first two pulses of cyclophosphamide (A).
Patients intolerant of cyclophosphamide
For cases where patients are intolerant of cyclophosphamide, alternative treatments such as methotrexate, azathioprine, leflunomide or mycophenolate mofetil may be used (B,C).
Maintenance therapy
Following achievement of successful remission, cyclophosphamide should be withdrawn and substituted with either azathioprine or methotrexate (A). Mycophenolate or leflunomide may be used as alternatives for intolerance or lack of efficacy of azathioprine or methotrexate (C). Patients should continue maintenance therapy for at least 24 months following successful disease remission (B). Patients with Wegener's granulomatosis or patients who remain ANCA positive should continue immunosuppression for up to 5 years (C).
Relapsing disease
Minor relapse is treated with an increase in prednisolone dosage and optimization of concurrent immunosuppression (C). Major relapse is treated with cyclophosphamide with an increase in prednisolone; intravenous methylprednisolone or plasma exchange may also be considered (C).
Refractory disease
The use of infliximab, intravenous immunoglobulin, antithymocyte globulin, CAMPATH-1H (alemtuzumab, anti-CD52), deoxyspergualin and rituximab in refractory disease is still under investigation (C). It is important to identify potential underlying factors influencing persistent or relapsing disease including infection and malignancy.
Assessment and monitoring of disease activity
Relapse may occur at anytime after diagnosis and remission induction. A validated tool should be used to assess disease activity and extent of disease (C). ANCA measurements are not closely associated with disease activity. Treatment should not be escalated solely on the basis of an increase in ANCA (B). Treatment withdrawal in patients with persistently positive ANCA is associated with relapse.
10. Detection and prevention of potential adverse effects of immunosuppressive therapy
Audit
This should include relapse rate, infection rate, mortality and cumulative doses of cyclophosphamide. 
